Retention Rate, Persistence and Safety of Adalimumab in Inflammatory Bowel Disease: A Real-Life, 9-Year, Single-Center Experience in Italy.
Dig Dis Sci
; 64(3): 863-874, 2019 03.
Article
in En
| MEDLINE
| ID: mdl-30334112
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Biological Products
/
Colitis, Ulcerative
/
Crohn Disease
/
Adalimumab
/
Anti-Inflammatory Agents
Type of study:
Diagnostic_studies
/
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Europa
Language:
En
Journal:
Dig Dis Sci
Year:
2019
Type:
Article
Affiliation country:
Italy